Loading
Life sciences · Journal article
Frontiers in Cellular and Infection Microbiology · October 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Based on the emerging evidence in the crosstalk between gut microbiota composition and the non-alcoholic fatty liver disease (NAFLD), the application of fecal microbiota transplantation (FMT) on patients with NAFLD has become an attractive research field. Evidence from multiple studies have proved that lean patients with NAFLD were more sensitive to FMT in both microbiomic and metabolic aspects compared to obese patients, and more benefits were observed in patients receiving allogenic FMT from lean donors compared to those receiving autologous FMT, possibly due to the benefits derived from the successful engraftment of donor’s microbiota post FMT. However, it has been observed from the clinical practice that an identified successful engraftment is not a promise of clinical efficacy in NAFLD patients. This review aims to summarize the current evidence supporting application of FMT in treatment of NAFLD. We realized that the clinical efficacy and long-term benefits of FMT on NAFLD patients warrant further investigation with more properly-designed randomized controlled trials.